Acquisition Battle Intensifies as Pfizer Faces Rival Bid for Metsera
Published on 10/31/2025 at 05:22 | Redaktion boerse-global.de
The pharmaceutical sector is witnessing a dramatic takeover contest as Pfizer confronts an unexpected challenge to its previously agreed acquisition. Competing firm Novo Nordisk has submitted a counterbid for the coveted biotechnology company Metsera, creating uncertainty about the deal’s outcome and placing Pfizer in a defensive position.
Metsera has officially confirmed receiving an unsolicited acquisition proposal from Novo Nordisk, describing the new offer as “superior” to the existing arrangement with Pfizer. This development represents a significant setback for the American pharmaceutical giant, which now finds its acquisition plans in jeopardy.
Novo Nordisk’s competing bid substantially exceeds the financial terms of Pfizer’s original agreement, transforming what appeared Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
